21 CFR 314.50 - Content and Format of an NDA

What it says

This section sets out what a new drug application must contain and how it is organized. It covers the application form, an index and summary, and technical sections including chemistry, manufacturing and controls, nonclinical pharmacology and toxicology, human pharmacokinetics and bioavailability, microbiology where relevant, clinical data and statistical analysis, together with samples, proposed labeling, patent information and required certifications.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• The chemistry, manufacturing and controls section is where an application connects to day-to-day manufacturing. It describes the drug substance and product, the manufacturers, the methods, the facilities and the controls, and the company commits to manufacturing as described.
• An approved application is a living commitment rather than a one-time filing. Later changes to what the application describes are managed through the post-approval change requirements, such as those in 21 CFR 314.70.
• The data supporting the application must be accurate, complete and traceable to original records, which ties the application to data integrity expectations in the laboratory and in manufacturing.

What FDA inspectors look for

• During pre-approval inspections, whether the actual process, equipment, specifications and batch records match what the application describes.
• Whether the data submitted in the application can be traced to original, contemporaneous records, including laboratory and development records.
• Whether the site is ready for commercial manufacture, with qualified equipment, validated processes and a functioning quality system.

Related regulations